Expanding contraceptive choices: Lunelle(TM) monthly contraceptive injection

Lee P. Shulman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Contraceptive options for women have expanded with the FDA approval of a monthly injectable contraceptive. Containing a progestin and estrogen (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate; Lunelle(TM)/Lunella(TM); Pharmacia and Upjohn), this novel once-a-month injection is characterized by the convenience and contraceptive efficacy of long-term reversible methods and the cycle control, return to fertility and side-effect profiles common to low-dose oral contraceptives. The association of these desirable attributes may increase the likelihood that a woman's chosen method will be used consistently and correctly to reduce the frequency of unintended pregnancy.

Original languageEnglish (US)
Pages (from-to)190-194
Number of pages5
JournalInternational journal of fertility and women's medicine
Issue number2
StatePublished - Mar 2000


  • Contraceptive
  • Estrogen
  • Injectable
  • Monthly
  • Progestin

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Expanding contraceptive choices: Lunelle(TM) monthly contraceptive injection'. Together they form a unique fingerprint.

Cite this